A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 570K | 275K | 900K | - |
| Net Income | -19M | -19M | - | - | - | -29M |
| EPS | $-8.88 | $-8.88 | $-43.68 | $-98.05 | $-163.80 | $-323.40 |
| Free Cash Flow | -16M | -16M | -21M | -19M | -25M | -29M |
| ROIC | - | - | - | - | - | -191.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | - | - | 0.03 | 0.03 | -0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -19M | -19M | -23M | -20M | -22M | -28M |
| Operating Margin | 0.0% | - | -4014.9% | -7238.5% | -2498.9% | - |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 2M | 2M | 3M | 1M | 0M | 0M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | N/A | 900K | 275K | 570K | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -21M | -27M | -32M | -28M | -22M | -20M | -23M | -19M | -19M |
| Op. Margin | N/A | N/A | N/A | N/A | -2498.9% | -7238.5% | -4014.9% | N/A | 0.0% |
| Net Income | -22M | -30M | -32M | -29M | N/A | N/A | N/A | -19M | -19M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | N/M | -97.8% | N/M | -191.3% | N/A | N/A | N/A | N/A | N/A |
| ROE | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| ROA | -393.4% | -134.0% | -692.1% | -246.5% | N/A | N/A | N/A | -598.5% | -717.8% |
| Cash Flow | |||||||||
| Op. Cash Flow | -21M | -25M | -31M | -29M | -25M | -19M | -21M | -16M | -16M |
| Free Cash Flow | -21M | -26M | -31M | -29M | -25M | -19M | -21M | -16M | -16M |
| Owner Earnings | -22M | -26M | -31M | -30M | -26M | -20M | -22M | -17M | -17M |
| CapEx | 68K | 235K | 78K | 290K | 32K | 99K | 67K | 22K | 22K |
| Maint. CapEx | 206K | 223K | 249K | 307K | 169K | 207K | 119K | 94K | 94K |
| Growth CapEx | 0 | 12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 206K | 223K | 249K | 307K | 169K | 207K | 119K | 94K | 94K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 319K | 177K | 447K | 732K | 541K | 545K | 474K | 341K | 341K |
| Debt Repayment | 0 | 0 | 0 | 50K | 9K | 75K | 74K | 76K | 76K |
| Balance Sheet | |||||||||
| Net Debt | -1.4M | N/A | N/A | -9.5M | -8.3M | -6.2M | -1.4M | -1.1M | 0 |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | 2.8M | N/A | N/A | 1.1M | 175K | 101K | 26K | 0 | N/A |
| Debt/Equity | -0.02 | -0.78 | -1.18 | -0.04 | 0.03 | 0.03 | N/A | N/A | 0.00 |
| Interest Coverage | -15.5 | -69.6 | N/A | -57.9 | -27.8 | -9953.0 | -22885.0 | -9367.5 | -9367.5 |
| Equity | -125M | -8.6M | -26M | -27M | 7.4M | 5.2M | N/A | N/A | 0 |
| Total Assets | 5.6M | 22M | 4.6M | 12M | 9.8M | 8.0M | 3.6M | 2.6M | 2.6M |
| Total Liabilities | 131M | 6.7M | 31M | 38M | 2.4M | 2.8M | N/A | N/A | N/A |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -187M | -217M | -249M | -277M | -300M | -320M | -340M | -359M | -359M |
| Working Capital | 809K | 17M | -2.9M | -1.9M | 7.1M | 4.9M | -2.6M | -2.6M | -2.6M |
| Current Assets | 5.0M | 21M | 4.0M | 11M | 9.4M | 7.5M | 3.3M | 2.5M | 2.5M |
| Current Liabilities | 4.2M | 4.4M | 6.9M | 13M | 2.3M | 2.5M | 5.9M | 5.1M | 5.1M |
| Per Share Data | |||||||||
| EPS | -4,179.00 | -1,186.50 | -518.70 | -323.40 | -163.80 | -98.05 | -43.68 | -8.88 | -8.88 |
| Owner EPS | -400.98 | -1,032.07 | -511.34 | -332.76 | -109.49 | -16.10 | -8.21 | -7.92 | -7.92 |
| Book Value | -2,295.72 | -346.53 | -427.11 | -297.89 | 31.20 | 4.22 | N/A | N/A | 0.00 |
| Cash Flow/Share | -391.37 | -1,015.99 | -500.01 | -321.11 | -106.51 | -15.49 | -7.99 | -7.71 | -8.84 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.1M | 0.0M | 0.1M | 0.1M | 0.2M | 1.2M | 2.7M | 2.1M | 2.1M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | 7.2 | 28.9 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | 134.2 | 955.6 | 303.8 | N/A | N/A |
| FCF Yield | N/A | -128.5% | -46.4% | -72.2% | -47.5% | -12.8% | -86.7% | -708.6% | -643.7% |
| Market Cap | N/A | 20M | 66M | 40M | 53M | 150M | 25M | 2.3M | 2.5M |
| Avg. Price | N/A | 1,536.32 | 1,138.62 | 860.02 | 508.38 | 213.37 | 64.70 | 5.83 | 1.20 |
| Year-End Price | N/A | 798.00 | 1,079.40 | 449.40 | 224.70 | 121.80 | 9.24 | 1.09 | 1.20 |
VACCINEX, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
VACCINEX, INC. (VCNX) has a 5-year average return on invested capital (ROIC) of -191.3%. This is below average and may indicate limited pricing power.
VACCINEX, INC. (VCNX) has a market capitalization of $3M. It is classified as a small-cap stock.
VACCINEX, INC. (VCNX) does not currently pay a regular dividend.
VACCINEX, INC. (VCNX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
VACCINEX, INC. (VCNX) generated $-16 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
VACCINEX, INC. (VCNX) reported earnings per share (EPS) of $-8.88 in its most recent fiscal year.
The Ledger Terminal provides 8 years of financial data for VACCINEX, INC. (VCNX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.